You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameKetamine
Accession NumberDB01221  (APRD00493)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (receptors, N-methyl-D-aspartate) and may interact with sigma receptors. [PubChem]
Structure
Thumb
Synonyms
(+-)-Ketamine
(±)-ketamine
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone
2-(methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone
DL-ketamine
Ketamina
KETAMINE
Ketaminum
NMDA
Special k
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
KetalarInjection10 mg/mLIntramuscular; IntravenousPar Pharmaceutical, Inc.2007-10-01Not applicableUs
KetalarInjection50 mg/mLIntramuscular; IntravenousPar Pharmaceutical, Inc.2007-10-01Not applicableUs
KetalarSolution10 mgIntramuscular; IntravenousErfa Canada 2012 Inc1972-12-31Not applicableCanada
KetalarInjection100 mg/mLIntramuscular; IntravenousPar Pharmaceutical, Inc.2007-10-01Not applicableUs
KetalarInjection10 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2012-10-17Not applicableUs
KetalarSolution50 mgIntramuscular; IntravenousErfa Canada 2012 Inc1972-12-31Not applicableCanada
Ketamine HydrochlorideInjection50 mg/mLIntramuscular; IntravenousPar Pharmaceutical Inc.2012-06-01Not applicableUs
Ketamine HydrochlorideInjection100 mg/mLIntramuscular; IntravenousPar Pharmaceutical Inc.2012-06-01Not applicableUs
Ketamine HydrochlorideInjection10 mg/mLIntramuscular; IntravenousPar Pharmaceutical Inc.2012-06-01Not applicableUs
Ketamine HydrochlorideInjection100 mg/mLIntramuscular; IntravenousREMEDYREPACK INC.2015-06-18Not applicableUs
Ketamine Hydrochloride Injection SdzSolution10 mgIntramuscular; IntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Ketamine Hydrochloride Injection SdzSolution50 mgIntramuscular; IntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Ketamine Hydrochloride Injection SdzSolution50 mgIntramuscular; IntravenousSandoz Canada Incorporated2013-08-12Not applicableCanada
Ketamine Hydrochloride Injection USPSolution10 mgIntramuscular; IntravenousSandoz Canada Incorporated2003-02-05Not applicableCanada
Ketamine Hydrochloride Injection USPSolution50 mgIntramuscular; IntravenousSandoz Canada Incorporated2003-02-04Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ketamine HydrochlorideInjection, solution10 mg/mLIntramuscular; IntravenousMylan Institutional LLC2008-10-01Not applicableUs
Ketamine HydrochlorideInjection, solution, concentrate100 mg/mLIntramuscular; IntravenousHospira, Inc.1996-06-27Not applicableUs
Ketamine HydrochlorideInjection, solution, concentrate50 mg/mLIntramuscular; IntravenousPhysicians Total Care, Inc.2002-03-12Not applicableUs
Ketamine HydrochlorideInjection50 mg/mLIntramuscular; IntravenousWest Ward Pharmaceuticals Corp1996-07-01Not applicableUs
Ketamine HydrochlorideInjection, solution, concentrate50 mg/mLIntramuscular; IntravenousHospira, Inc.1996-06-27Not applicableUs
Ketamine HydrochlorideInjection, solution50 mg/mLIntramuscular; IntravenousMylan Institutional LLC2002-02-01Not applicableUs
Ketamine HydrochlorideInjection100 mg/mLIntramuscular; IntravenousWest Ward Pharmaceuticals Corp1996-07-01Not applicableUs
Ketamine HydrochlorideInjection, solution, concentrate50 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2012-10-11Not applicableUs
Ketamine HydrochlorideInjection, solution100 mg/mLIntramuscular; IntravenousMylan Institutional LLC2003-03-01Not applicableUs
Ketamine HydrochlorideInjection, solution, concentrate100 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2012-10-16Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
KetajectBristol-Myers Squibb
KetanestParke Davis
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ketamine hydrochloride
1867-66-9
Thumb
  • InChI Key: VCMGMSHEPQENPE-UHFFFAOYNA-N
  • Monoisotopic Mass: 273.068719585
  • Average Mass: 274.186
DBSALT000396
Categories
UNII690G0D6V8H
CAS number6740-88-1
WeightAverage: 237.725
Monoisotopic: 237.092041846
Chemical FormulaC13H16ClNO
InChI KeyYQEZLKZALYSWHR-UHFFFAOYSA-N
InChI
InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3
IUPAC Name
2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
SMILES
CNC1(CCCCC1=O)C1=CC=CC=C1Cl
Pharmacology
IndicationFor use as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation.
Structured Indications Not Available
PharmacodynamicsKetamine is a rapid-acting general anesthetic producing an anesthetic state characterized by profound analgesia, normal pharyngeal-laryngeal reflexes, normal or slightly enhanced skeletal muscle tone, cardiovascular and respiratory stimulation, and occasionally a transient and minimal respiratory depression. Ketamine is indicated as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation. The anesthetic state produced by Ketamine has been termed “dissociative anesthesia” in that it appears to selectively interrupt association pathways of the brain before producing somesthetic sensory blockade. It may selectively depress the thalamoneocortical system before significantly obtunding the more ancient cerebral centers and pathways (reticularactivating and limbic systems).
Mechanism of actionKetamine has several clinically useful properties, including analgesia and less cardiorespiratory depressant effects than other anaesthetic agents, it also causes some stimulation of the cardiocascular system. Ketamine has been reported to produce general as well as local anaesthesia. It interacts with N-methyl-D-aspartate (NMDA) receptors, opioid receptors, monoaminergic receptors, muscarinic receptors and voltage sensitive Ca ion channels. Unlike other general anaesthetic agents, ketamine does not interact with GABA receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glutamate receptor ionotropic, NMDA 3AProteinyes
antagonist
HumanQ8TCU5 details
Substance-P receptorProteinunknown
antagonist
HumanP25103 details
D(2) dopamine receptorProteinunknown
agonist
partial agonist
HumanP14416 details
Delta-type opioid receptorProteinunknown
binder
HumanP41143 details
Sodium-dependent noradrenaline transporterProteinunknownNot AvailableHumanP23975 details
Kappa-type opioid receptorProteinunknown
agonist
HumanP41145 details
Mu-type opioid receptorProteinunknown
binder
HumanP35372 details
Muscarinic acetylcholine receptorProtein groupunknown
binder
Humannot applicabledetails
5-hydroxytryptamine receptor 2Protein groupunknown
antagonist
Humannot applicabledetails
5-hydroxytryptamine receptor 1Protein groupunknown
antagonist
Humannot applicabledetails
Related Articles
AbsorptionRapidly absorbed following parenteral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

SubstrateEnzymesProduct
Ketamine
NorketamineDetails
Ketamine
Not Available
6-HydroxyketamineDetails
Ketamine
Not Available
5-HydroxyketamineDetails
Ketamine
Not Available
4-HydroxyketamineDetails
Norketamine
Not Available
4-HydroxynorketamineDetails
Norketamine
Not Available
5-HydroxynorketamineDetails
Norketamine
Not Available
6-HydroxynorketamineDetails
6-Hydroxyketamine
Not Available
6-HydroxynorketamineDetails
5-Hydroxyketamine
Not Available
5-HydroxynorketamineDetails
4-Hydroxyketamine
Not Available
4-HydroxynorketamineDetails
Route of eliminationNot Available
Half life2.5-3 hours.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Ketamine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ketamine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Ketamine can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Ketamine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Ketamine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Ketamine.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Ketamine is combined with adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Ketamine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Ketamine is combined with Agomelatine.Approved, Investigational
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Ketamine.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Ketamine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ketamine.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Ketamine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ketamine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ketamine.Approved, Illicit, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Ketamine.Approved, Investigational
AmiodaroneThe metabolism of Ketamine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ketamine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Ketamine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Ketamine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ketamine is combined with Amperozide.Experimental
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Ketamine.Approved
AprepitantThe serum concentration of Ketamine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Ketamine is combined with Aripiprazole.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Ketamine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Ketamine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Ketamine is combined with Asenapine.Approved
AtazanavirThe metabolism of Ketamine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Ketamine.Approved
AtomoxetineThe metabolism of Ketamine can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Ketamine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Azaperone.Vet Approved
AzelastineKetamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Ketamine is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Ketamine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Ketamine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ketamine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ketamine is combined with Benzyl alcohol.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Ketamine.Approved, Vet Approved
BexaroteneThe serum concentration of Ketamine can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Ketamine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Ketamine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ketamine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ketamine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ketamine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ketamine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Bromazepam.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Ketamine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Ketamine is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ketamine.Approved, Investigational
BuprenorphineKetamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ketamine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ketamine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Ketamine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Ketamine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Ketamine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ketamine.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Ketamine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Ketamine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Ketamine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Ketamine.Approved
CapecitabineThe metabolism of Ketamine can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Ketamine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Ketamine is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Ketamine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Ketamine is combined with Carisoprodol.Approved
CelecoxibThe metabolism of Ketamine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Ketamine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ketamine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Ketamine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ketamine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Ketamine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ketamine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlorphenamine.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Ketamine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Ketamine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Ketamine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ketamine.Approved, Vet Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Ketamine.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Ketamine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Ketamine.Approved
ClarithromycinThe metabolism of Ketamine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Ketamine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Ketamine is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Ketamine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Ketamine is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Ketamine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Ketamine.Approved
ClopidogrelThe metabolism of Ketamine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ketamine.Approved, Illicit
ClotrimazoleThe metabolism of Ketamine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Ketamine.Approved
CobicistatThe metabolism of Ketamine can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Ketamine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ketamine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ketamine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Ketamine.Approved
ConivaptanThe serum concentration of Ketamine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ketamine.Approved
CrizotinibThe metabolism of Ketamine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketamine.Approved
CyclosporineThe metabolism of Ketamine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ketamine.Approved
DabrafenibThe serum concentration of Ketamine can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Ketamine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Ketamine is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Ketamine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ketamine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Ketamine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Ketamine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Ketamine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Ketamine.Approved
DeferasiroxThe serum concentration of Ketamine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ketamine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Ketamine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ketamine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Ketamine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ketamine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Ketamine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ketamine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Ketamine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ketamine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ketamine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Ketamine.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ketamine.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Ketamine is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Ketamine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ketamine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Ketamine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Ketamine.Illicit
DiltiazemThe metabolism of Ketamine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Ketamine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ketamine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ketamine.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Ketamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Ketamine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Ketamine.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Ketamine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Ketamine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ketamine.Approved, Investigational
DoxycyclineThe metabolism of Ketamine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ketamine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Illicit
DronedaroneThe metabolism of Ketamine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Ketamine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ketamine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Ketamine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Ketamine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Ketamine.Approved
EfavirenzThe serum concentration of Ketamine can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Ketamine.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ketamine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Ketamine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Ketamine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Ketamine.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Ketamine.Approved, Investigational
ErythromycinThe metabolism of Ketamine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Ketamine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Ketamine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ketamine.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Ketamine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Ketamine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Ketamine.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ketamine.Approved
EthanolKetamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketamine.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ketamine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Ketamine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Ketamine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Ketamine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ketamine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Ketamine.Approved
EtorphineThe risk or severity of adverse effects can be increased when Ketamine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Ketamine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ketamine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Ketamine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Ketamine is combined with Felbamate.Approved
FelodipineThe metabolism of Ketamine can be decreased when combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ketamine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Ketamine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Ketamine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Ketamine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Ketamine is combined with Flibanserin.Approved
FloxuridineThe metabolism of Ketamine can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Ketamine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Ketamine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Ketamine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ketamine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ketamine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ketamine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Ketamine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Ketamine can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Ketamine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Ketamine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ketamine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Ketamine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Ketamine is combined with Fospropofol.Approved, Illicit
Fusidic AcidThe serum concentration of Ketamine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ketamine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ketamine is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Ketamine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Ketamine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Ketamine.Approved
GemfibrozilThe metabolism of Ketamine can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Ketamine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Ketamine is combined with Glutethimide.Approved, Illicit
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Ketamine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Ketamine.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Ketamine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ketamine.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Ketamine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ketamine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Ketamine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Hexobarbital.Approved
HydrocodoneKetamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Ketamine.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketamine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Ketamine.Approved
IdelalisibThe serum concentration of Ketamine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Iloperidone.Approved
ImatinibThe metabolism of Ketamine can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Ketamine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Ketamine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ketamine is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Ketamine can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Ketamine.Approved, Investigational
IrbesartanThe metabolism of Ketamine can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Ketamine.Approved, Investigational
IsavuconazoniumThe metabolism of Ketamine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ketamine.Approved, Vet Approved
IsradipineThe metabolism of Ketamine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Ketamine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ketamine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Ketamine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Ketamine can be decreased when combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Ketamine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Ketamine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Ketamine.Approved, Investigational
LapatinibThe metabolism of Ketamine can be decreased when combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Ketamine.Approved
LeflunomideThe metabolism of Ketamine can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Ketamine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Ketamine.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Ketamine.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ketamine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Ketamine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Ketamine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Ketamine is combined with Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Ketamine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Ketamine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Ketamine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ketamine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ketamine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Ketamine.Approved
LithiumThe risk or severity of adverse effects can be increased when Ketamine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Ketamine is combined with Lofentanil.Illicit
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Ketamine.Approved
LopinavirThe metabolism of Ketamine can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Ketamine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ketamine.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Ketamine.Approved
LovastatinThe metabolism of Ketamine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ketamine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Ketamine is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Ketamine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ketamine can be increased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Vet Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Ketamine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Ketamine is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Ketamine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Ketamine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Melperone.Approved
MemantineThe risk or severity of adverse effects can be increased when Ketamine is combined with Memantine.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ketamine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ketamine.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ketamine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Ketamine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ketamine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ketamine is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Ketamine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Ketamine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ketamine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Ketamine.Approved
MethotrimeprazineKetamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ketamine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Ketamine is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ketamine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Ketamine.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Ketamine.Approved, Investigational
MetyrosineKetamine may increase the sedative activities of Metyrosine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Ketamine.Approved, Illicit
MifepristoneThe serum concentration of Ketamine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Ketamine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Ketamine.Approved
MirtazapineKetamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Ketamine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Ketamine.Approved, Investigational
ModafinilThe serum concentration of Ketamine can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Molindone.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Ketamine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ketamine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Ketamine.Approved
NafcillinThe serum concentration of Ketamine can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ketamine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ketamine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Ketamine.Approved, Vet Approved
NefazodoneThe metabolism of Ketamine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Ketamine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ketamine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ketamine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Ketamine can be decreased when combined with Nicardipine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Ketamine.Approved
NilotinibThe metabolism of Ketamine can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ketamine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Ketamine is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Ketamine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Ketamine is combined with Nortriptyline.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Ketamine.Approved, Investigational
OlaparibThe metabolism of Ketamine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Ketamine is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Ketamine.Approved
OmeprazoleThe metabolism of Ketamine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ketamine.Approved
OpiumThe risk or severity of adverse effects can be increased when Ketamine is combined with Opium.Approved, Illicit
OrphenadrineKetamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ketamine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Ketamine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ketamine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Ketamine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Ketamine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ketamine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ketamine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ketamine.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Ketamine.Approved, Vet Approved
PalbociclibThe serum concentration of Ketamine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Ketamine.Approved, Investigational
ParaldehydeKetamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Ketamine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ketamine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ketamine.Approved, Vet Approved
PentobarbitalThe metabolism of Ketamine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved
PerazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Ketamine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ketamine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ketamine.Approved
PhenobarbitalThe metabolism of Ketamine can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ketamine is combined with Phenoxyethanol.Approved
PhenytoinThe metabolism of Ketamine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ketamine.Approved
PioglitazoneThe metabolism of Ketamine can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Ketamine is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ketamine.Approved
PizotifenThe risk or severity of adverse effects can be increased when Ketamine is combined with Pizotifen.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Ketamine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Ketamine.Approved
PosaconazoleThe metabolism of Ketamine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleKetamine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Ketamine is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Ketamine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Ketamine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Ketamine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Ketamine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ketamine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Ketamine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ketamine.Approved
PrimidoneThe metabolism of Ketamine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ketamine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ketamine.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Ketamine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ketamine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ketamine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ketamine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Ketamine is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Ketamine.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Ketamine is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Ketamine.Approved
PSD502The risk or severity of adverse effects can be increased when Ketamine is combined with PSD502.Investigational
PyrimethamineThe metabolism of Ketamine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Ketamine can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Ketamine.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Ketamine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Ketamine.Approved
RabeprazoleThe metabolism of Ketamine can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Ketamine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ketamine is combined with Ramelteon.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Ketamine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Ketamine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ketamine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ketamine.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Ketamine.Approved
RifabutinThe metabolism of Ketamine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ketamine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ketamine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Ketamine.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Ketamine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ketamine is combined with Ritanserin.Investigational
RitonavirThe metabolism of Ketamine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Ketamine.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Ketamine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Romifidine.Vet Approved
RopiniroleKetamine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ketamine.Approved
RosiglitazoneThe metabolism of Ketamine can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotineKetamine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ketamine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Ketamine is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Ketamine is combined with Sage 547.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Ketamine.Approved, Vet Approved
SaquinavirThe metabolism of Ketamine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Ketamine can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Ketamine.Approved
SertindoleThe risk or severity of adverse effects can be increased when Ketamine is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Ketamine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Ketamine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Ketamine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ketamine.Approved
SiltuximabThe serum concentration of Ketamine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ketamine can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Ketamine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Ketamine.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Ketamine.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Ketamine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Ketamine.Experimental
St. John's WortThe serum concentration of Ketamine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Ketamine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ketamine.Approved, Investigational
SulfadiazineThe metabolism of Ketamine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Ketamine can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Ketamine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ketamine.Approved
SuvorexantKetamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Ketamine.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Ketamine.Approved
TandospironeThe risk or severity of adverse effects can be increased when Ketamine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ketamine is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Ketamine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Ketamine.Approved
TelaprevirThe metabolism of Ketamine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Ketamine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ketamine.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Ketamine.Approved
TeriflunomideThe metabolism of Ketamine can be decreased when combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Ketamine is combined with Tetrodotoxin.Investigational
ThalidomideKetamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ketamine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Ketamine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ketamine.Approved
ThiotepaThe metabolism of Ketamine can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Ketamine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ketamine is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Ketamine.Approved
TiclopidineThe metabolism of Ketamine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Ketamine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Ketamine can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Ketamine can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Ketamine is combined with Tolcapone.Approved, Withdrawn
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Ketamine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Ketamine is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Ketamine.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Ketamine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ketamine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ketamine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Ketamine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ketamine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ketamine.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ketamine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ketamine.Approved, Vet Approved
TrimethoprimThe metabolism of Ketamine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Ketamine is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Ketamine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Ketamine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ketamine.Approved, Investigational
ValsartanThe metabolism of Ketamine can be decreased when combined with Valsartan.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Ketamine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Ketamine.Approved
VenlafaxineThe metabolism of Ketamine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Ketamine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Ketamine is combined with Vigabatrin.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Ketamine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Ketamine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Ketamine.Approved
VoriconazoleThe metabolism of Ketamine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Xylazine.Vet Approved
ZafirlukastThe metabolism of Ketamine can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ketamine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ketamine is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Ketamine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ketamine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Zolazepam.Vet Approved
ZolpidemKetamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Ketamine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ketamine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Ketamine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Ketamine is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

John A. Flores, Kenton L. Crowley, “Process for the preparation of ketamine ointment.” U.S. Patent US5817699, issued June, 1995.

US5817699
General References
  1. Harrison NL, Simmonds MA: Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol. 1985 Feb;84(2):381-91. [PubMed:2858237 ]
  2. Bergman SA: Ketamine: review of its pharmacology and its use in pediatric anesthesia. Anesth Prog. 1999 Winter;46(1):10-20. [PubMed:10551055 ]
  3. Bonanno FG: Ketamine in war/tropical surgery (a final tribute to the racemic mixture). Injury. 2002 May;33(4):323-7. [PubMed:12091028 ]
  4. Lankenau SE, Sanders B, Bloom JJ, Hathazi D, Alarcon E, Tortu S, Clatts MC: First injection of ketamine among young injection drug users (IDUs) in three U.S. cities. Drug Alcohol Depend. 2007 Mar 16;87(2-3):183-93. Epub 2006 Sep 18. [PubMed:16979848 ]
  5. Reboso Morales JA, Gonzalez Miranda F: [Ketamine]. Rev Esp Anestesiol Reanim. 1999 Mar;46(3):111-22. [PubMed:10228376 ]
External Links
ATC CodesN01AX03
AHFS Codes
  • 28:04.00
  • 28:04.92
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (67.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9974
Blood Brain Barrier+0.9826
Caco-2 permeable+0.6326
P-glycoprotein substrateSubstrate0.5753
P-glycoprotein inhibitor INon-inhibitor0.5948
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.6737
CYP450 2C9 substrateNon-substrate0.6363
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.7323
CYP450 2C9 inhibitorNon-inhibitor0.7985
CYP450 2D6 inhibitorNon-inhibitor0.6912
CYP450 2C19 inhibitorNon-inhibitor0.5347
CYP450 3A4 inhibitorNon-inhibitor0.8253
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5426
Ames testNon AMES toxic0.7223
CarcinogenicityNon-carcinogens0.8878
BiodegradationNot ready biodegradable0.9937
Rat acute toxicity2.3939 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8859
hERG inhibition (predictor II)Inhibitor0.6047
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
InjectionIntramuscular; Intravenous10 mg/mL
InjectionIntramuscular; Intravenous100 mg/mL
InjectionIntramuscular; Intravenous50 mg/mL
SolutionIntramuscular; Intravenous50 mg
Injection, solutionIntramuscular; Intravenous10 mg/mL
Injection, solutionIntramuscular; Intravenous100 mg/mL
Injection, solutionIntramuscular; Intravenous50 mg/mL
Injection, solution, concentrateIntramuscular; Intravenous100 mg/mL
Injection, solution, concentrateIntramuscular; Intravenous50 mg/mL
SolutionIntramuscular; Intravenous10 mg
Prices
Unit descriptionCostUnit
Ketamine hcl powder7.22USD g
Ketamine hcl-ns 50 mg/5 ml syr2.82USD ml
Ketamine 100 mg/ml vial2.36USD ml
Ketalar 100 mg/ml vial1.95USD ml
Ketamine hcl-ns 100 mg/10 ml1.95USD ml
Ketamine HCl 50 mg/ml Solution1.77USD ml
Ketalar 10 mg/ml vial0.99USD ml
Ketamine 10 mg/ml vial0.99USD ml
Ketalar 50 mg/ml vial0.75USD ml
Ketamine 50 mg/ml vial0.61USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point92-93U.S. Patent 3,254,124.
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0464 mg/mLALOGPS
logP2.69ALOGPS
logP3.35ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)18.78ChemAxon
pKa (Strongest Basic)7.45ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.1 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity65.55 m3·mol-1ChemAxon
Polarizability24.97 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as chlorobenzenes. These are compounds containing one or more chlorine atoms attached to a benzene moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassHalobenzenes
Direct ParentChlorobenzenes
Alternative Parents
Substituents
  • Aralkylamine
  • Cyclohexylamine
  • Cyclohexanone
  • Chlorobenzene
  • Aryl halide
  • Aryl chloride
  • Cyclic ketone
  • Ketone
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein phosphatase 2a binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity).
Gene Name:
GRIN3A
Uniprot ID:
Q8TCU5
Molecular Weight:
125464.07 Da
References
  1. Smothers CT, Woodward JJ: Pharmacological characterization of glycine-activated currents in HEK 293 cells expressing N-methyl-D-aspartate NR1 and NR3 subunits. J Pharmacol Exp Ther. 2007 Aug;322(2):739-48. Epub 2007 May 14. [PubMed:17502428 ]
  2. Harrison NL, Simmonds MA: Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol. 1985 Feb;84(2):381-91. [PubMed:2858237 ]
  3. Sinner B, Graf BM: Ketamine. Handb Exp Pharmacol. 2008;(182):313-33. doi: 10.1007/978-3-540-74806-9_15. [PubMed:18175098 ]
  4. Radovanovic D, Pjevic M: [Ketamine: the past 30 years and its future]. Med Pregl. 2003 Sep-Oct;56(9-10):439-45. [PubMed:14740534 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Tachykinin receptor activity
Specific Function:
This is a receptor for the tachykinin neuropeptide substance P. It is probably associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: substance P > substance K > neuromedin-K.
Gene Name:
TACR1
Uniprot ID:
P25103
Molecular Weight:
46250.5 Da
References
  1. Okamoto T, Minami K, Uezono Y, Ogata J, Shiraishi M, Shigematsu A, Ueta Y: The inhibitory effects of ketamine and pentobarbital on substance p receptors expressed in Xenopus oocytes. Anesth Analg. 2003 Jul;97(1):104-10, table of contents. [PubMed:12818951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonistpartial agonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Seeman P, Guan HC, Hirbec H: Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse. 2009 Aug;63(8):698-704. doi: 10.1002/syn.20647. [PubMed:19391150 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Smith DJ, Pekoe GM, Martin LL, Coalgate B: The interaction of ketamine with the opiate receptor. Life Sci. 1980 Mar 10;26(10):789-95. [PubMed:6246318 ]
  2. Hustveit O, Maurset A, Oye I: Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995 Dec;77(6):355-9. [PubMed:8835358 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Salt PJ, Barnes PK, Beswick FJ: Inhibition of neuronal and extraneuronal uptake of noradrenaline by ketamine in the isolated perfused rat heart. Br J Anaesth. 1979 Sep;51(9):835-8. [PubMed:508488 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Smith DJ, Pekoe GM, Martin LL, Coalgate B: The interaction of ketamine with the opiate receptor. Life Sci. 1980 Mar 10;26(10):789-95. [PubMed:6246318 ]
  2. Hustveit O, Maurset A, Oye I: Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995 Dec;77(6):355-9. [PubMed:8835358 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Smith DJ, Pekoe GM, Martin LL, Coalgate B: The interaction of ketamine with the opiate receptor. Life Sci. 1980 Mar 10;26(10):789-95. [PubMed:6246318 ]
  2. Hustveit O, Maurset A, Oye I: Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995 Dec;77(6):355-9. [PubMed:8835358 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Components:
NameUniProt IDDetails
Muscarinic acetylcholine receptor M1P11229 Details
Muscarinic acetylcholine receptor M2P08172 Details
Muscarinic acetylcholine receptor M3P20309 Details
Muscarinic acetylcholine receptor M4P08173 Details
Muscarinic acetylcholine receptor M5P08912 Details
References
  1. Hustveit O, Maurset A, Oye I: Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995 Dec;77(6):355-9. [PubMed:8835358 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates phospholipase C and a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and promotes the release of Ca(2+) ions from intracellular stores. Affects neural activity, perception, cognition and mood. Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction.(Microbial infection) Acts as a receptor for human JC polyomavirus/JCPyV.
Components:
NameUniProt IDDetails
5-hydroxytryptamine receptor 2AP28223 Details
5-hydroxytryptamine receptor 2BP41595 Details
5-hydroxytryptamine receptor 2CP28335 Details
References
  1. Martin LL, Bouchal RL, Smith DJ: Ketamine inhibits serotonin uptake in vivo. Neuropharmacology. 1982 Feb;21(2):113-8. [PubMed:6460944 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism. Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior. Plays a role in the response to anxiogenic stimuli.
Components:
NameUniProt IDDetails
5-hydroxytryptamine receptor 1AP08908 Details
5-hydroxytryptamine receptor 1BP28222 Details
5-hydroxytryptamine receptor 1DP28221 Details
5-hydroxytryptamine receptor 1EP28566 Details
5-hydroxytryptamine receptor 1FP30939 Details
References
  1. Martin LL, Bouchal RL, Smith DJ: Ketamine inhibits serotonin uptake in vivo. Neuropharmacology. 1982 Feb;21(2):113-8. [PubMed:6460944 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23